Consolidated Statements of Operations (unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended			6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012		Jun. 30, 2013	Jun. 30, 2012
Income Statement [Abstract]
Revenue from product sales	$ 62	$ 28	[1]	$ 88	$ 44	[1]
Cost of sales	2,242	2,094	[1]	4,593	3,647	[1]
Gross loss	(2,180)	(2,066)	[1]	(4,505)	(3,603)	[1]
Selling, general and administrative expenses	2,450	3,239	[1]	4,817	6,962	[1]
Research and development expenses	1,184	388	[1]	2,396	868	[1]
Operating loss	(5,814)	(5,693)	[1]	(11,718)	(11,433)	[1]
Other income (expense)
Warrant income (expense)	(375)	3,148	[1]	(317)	2,647	[1]
Derivative revaluation expense		(1,952)	[1]		(1,917)	[1]
Interest expense		(197)	[1]		(446)	[1]
Extinguishment of debt		(4,421)	[1]		(4,421)	[1]
Loss from continuing operations before income taxes	(6,189)	(9,115)	[1]	(12,035)	(15,570)	[1]
Deferred tax benefit		0			2,500	[1]
Loss from continuing operations	(6,189)	(9,115)	[1]	(12,035)	(13,070)	[1]
Income (loss) from discontinued operations, net of tax	(5)	1	[1]	(9)	(6)	[1]
Net loss	(6,194)	(9,114)	[1]	(12,044)	(13,076)	[1]
Net income attributable to noncontrolling interest		(9)	[1]		(20)	[1]
Net loss attributable to Fibrocell Science, Inc. common shareholders	$ (6,194)	$ (9,123)	[1]	$ (12,044)	$ (13,096)	[1]
Per share information:
Loss from continued operations before income taxes-basic and diluted	$ (0.24)	$ (2.35)	[1]	$ (0.46)	$ (4.04)	[1]
Income from deferred tax benefit					$ 0.65	[1]
Net loss attributable to common shareholders per common share-basic and diluted	$ (0.24)	$ (2.35)	[1]	$ (0.46)	$ (3.39)	[1]
Weighted average number of basic and diluted common shares outstanding	26,230,802	3,871,925	[1]	26,230,358	3,852,297	[1]

[1] Restated